Skip to main content

Table 6 Cox regression analyses of validated risk factors for melanoma

From: Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

 

Univariate

Multivariate

Factor

HR

95% CI

p-value

HR

95% CI

p-value

Age

 50 – 59

1.53

0.70 – 3.34

0.285

1.53

0.70 – 3.34

0.285

 60 – 69

1.62

0.74 – 3.55

0.230

1.62

0.74 – 3.54

0.230

 ≥ 70

1.35

0.55 – 3.30

0.507

1.35

0.55 – 3.30

0.507

Breslow’s index

 1.01 – 2.00 mm

0.79

0.39 – 1.59

0.502

0.79

0.39 – 1.59

0.502

 2.01 – 4.00 mm

0.59

0.27 – 1.29

0.182

0.59

0.27 – 1.29

0.182

 ≥ 4.01 mm

1.55

0.61 – 3.92

0.356

1.55

0.61–3.92

0.356

Sex

 female

1.72

0.98 – 3.06

0.059

1.72

0.98 – 3.06

0.059

Histologic subtype

 nodular type

1.29

0.55 – 3.02

0.553

1.29

0.55 – 3.02

0.553

Mutational status

 BRAF

0.46

0.20 – 1.07

0.072

0.46

0.20 – 1.07

0.072

 NRAS

0.70

0.33 – 1.47

0.346

0.70

0.33 – 1.47

0.346

SLNB

 positive

2.65

1.15 – 6.10

0.022*

2.65

1.15 – 6.10

0.022*

Treatment

 targeted therapy

1.10

0.49 – 2.46

0.821

1.10

0.49 – 2.46

0.821

 ICB

0.17

0.06 – 0.48

0.001***

0.17

0.06 – 0.48

0.001***

 chemotherapy

0.57

0.25 – 1.29

0.175

0.57

0.25 – 1.29

0.175

  1. Univariate and multivariate analysis on survival from the primary diagnosis (OS) of melanoma. Validated risk factors, the mutational status, and therapies were assessed with Cox proportional hazard regression. The references for each factor were age < 50 years, male sex, Breslow’s thickness < 1.00 mm, negative SLNB status, WT for BRAF and NRAS, non-nodular subtype, and no systemic therapy. Hazard ratios (HR) for death and 95% confidence intervals (CI) are indicated; SLNB sentinel lymph node biopsy, ICB immune checkpoint blockade; *p < 0.05, ***p < 0.001
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us